EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery

Yidi Jiang, Shuangmei Li, Elisa A Liehn, Chee Seng Chan, Ji Xin Tan, Tian Xin Phua, Shing Leng Chan, Choon Keong Lee, Xiangliang Lin, Natalie Jun Hui Soh, Gabriele Grassi, Jiong-Wei Wang und 6 weitere

Journal of Controlled Release · 2026-12 · 400 · 115504

DOI: 10.1016/j.jconrel.2026.115504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Yidi Jiang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore 117544, Singapore. Die Arbeit nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Medical Research Council, Government of Singapore Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by steatosis, inflammation, and progressive fibrosis. Increasing evidence suggests that cellular senescence contributes to MASH progression by promoting lipid accumulation, inflammatory signaling, and fibrogenic responses, highlighting hepatic senescent cells as a potential therapeutic target. Senolytics selectively eliminate senescent cells, but their application in MASH remains insufficiently explored. In this study, we developed in vitro models integrating hepatic lipid accumulation and hepatocyte-macrophage inflammatory crosstalk to facilitate investigation of the contribution of cellular senescence to MASH pathology and to evaluate senescence-targeted interventions. Senescent hepatic cells showed enhanced lipid accumulation and amplified inflammatory signaling with macrophages. Natural Extracellular Vesicles (EVs) derived from adipocytes reduced senescence-associated phenotypes but exhibited context-dependent biological effects, highlighting the limited control over their intrinsic bioactivity. Navitoclax, a senolytic targeting anti-apoptotic BCL-2 family proteins, reduced senescence-associated phenotypes, but its clinical use is limited by its dose-dependent toxicity. Hence, we conceived nano-Cell Vesicle Technology Systems (nCVTs), a biohybrid-based platform combining cell-derived membranes with synthetic lipids for controlled delivery of navitoclax. Navitoclax-loaded nCVTs retained senolytic activity and reduced inflammatory signaling and fibrotic activation in vitro. Importantly, in a Western diet- and fructose-induced (WDF) MASH mouse model, navitoclax-loaded AML-12-derived nCVTs alleviated hepatic lipid accumulation while reducing histopathological activity score and fibrotic profiles. Neither navitoclax formulation reduced platelet counts or hemoglobin concentrations at the tested dose. Collectively, these findings support cellular senescence as a therapeutically relevant target for MASH and identify nCVTs as a promising engineered platform for controlled senolytic delivery.

Schlagwörter

Stichwörter der Autor:innen

Biohybrid nanocarriersCellular senescenceMetabolic dysfunction-associated steatohepatitis (MASH)Nano-Cell Vesicle Technology Systems (nCVTs)Senolytic delivery

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore 117544, Singapore.
  • Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore 117544, Singapore; Department of Emergency, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 5…
  • Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; National Heart Centre, 5 Hospital Drive, Singapore 169609, Singapore.
  • Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
  • Esco Aster Pte. Ltd, #02-01, Blk 67 Ayer Rajah Crescent, Singapore 139950, Singapore.
  • Clinical Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.

Förderung

  • National Medical Research Council
  • Government of Singapore Ministry of Education

Zitieren

APA

Jiang, Y., Li, S., Liehn, E. A., Chan, C. S., Tan, J. X., Phua, T. X., Chan, S. L., Lee, C. K., Lin, X., Soh, N. J. H., Grassi, G., Wang, J. W., Wang, T., Singh, B. K., Tripathi, M., Toh, W. S., Yu, V. C., & Pastorin, G. (2026). Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery. Journal of Controlled Release, 400, 115504. https://doi.org/10.1016/j.jconrel.2026.115504

Vancouver

Jiang Y, Li S, Liehn EA, Chan CS, Tan JX, Phua TX, et al. Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery. Journal of Controlled Release. 2026;400:115504. doi:10.1016/j.jconrel.2026.115504

BibTeX
@article{Jiang2026,
  author = {Jiang, Yidi and Li, Shuangmei and Liehn, Elisa A and Chan, Chee Seng and Tan, Ji Xin and Phua, Tian Xin and Chan, Shing Leng and Lee, Choon Keong and Lin, Xiangliang and Soh, Natalie Jun Hui and Grassi, Gabriele and Wang, Jiong-Wei and Wang, Tong and Singh, Brijesh Kumar and Tripathi, Madhulika and Toh, Wei Seong and Yu, Victor C and Pastorin, Giorgia},
  title = {Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {400},
  pages = {115504},
  doi = {10.1016/j.jconrel.2026.115504}
}
Kostenlos starten →